share_log

榮昌生物:截至二零二四年三月三十一日止月份之股份發行人的證券變動月報表

REMEGEN: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

香港交易所 ·  Apr 8 04:46
Summary by Moomoo AI
榮昌生物製藥(煙台)股份有限公司於2024年4月8日向香港交易及結算所有限公司提交了最新的證券變動月報表,報告截至2024年3月31日的股份變動情況。報告顯示,公司的H類普通股股份數目在香港聯交所上市的部分於本月內無增減,結存為189,581,239股,每股面值1人民幣。A類普通股在上海證券交易所上市的部分亦無增減,結存為354,750,844股。此外,根據2022年及2023年的A股股票激勵計劃,公司可能會發行新的A類普通股股份,總數為2,498,330股。公司確認,所有證券發行均已獲得董事會批准,並符合相關法律規定。
榮昌生物製藥(煙台)股份有限公司於2024年4月8日向香港交易及結算所有限公司提交了最新的證券變動月報表,報告截至2024年3月31日的股份變動情況。報告顯示,公司的H類普通股股份數目在香港聯交所上市的部分於本月內無增減,結存為189,581,239股,每股面值1人民幣。A類普通股在上海證券交易所上市的部分亦無增減,結存為354,750,844股。此外,根據2022年及2023年的A股股票激勵計劃,公司可能會發行新的A類普通股股份,總數為2,498,330股。公司確認,所有證券發行均已獲得董事會批准,並符合相關法律規定。
Wing Cheong Biopharmaceuticals (Yantai) Co., Ltd. filed with Hong Kong Trading and Settlement Limited on April 8, 2024 its latest Securities Changes Monthly Report, reporting stock changes for the year ended March 31, 2024. The report showed that the Company's number of Class H ordinary shares listed on the Hong Kong Stock Exchange did not decrease during the month, amounting to 189,581,239 shares with a face value of RMB 1 per share. The share of Class A ordinary shares listed on the Shanghai Stock Exchange did not increase, amounting to 354,750,844 shares. In addition, under the A share incentive plan for 2022 and 2023, the company may issue new Class A ordinary shares totaling 2,498,330 shares. The Company confirms that all securities issues have been approved by the Board of Directors and are in compliance with relevant legal requirements.
Wing Cheong Biopharmaceuticals (Yantai) Co., Ltd. filed with Hong Kong Trading and Settlement Limited on April 8, 2024 its latest Securities Changes Monthly Report, reporting stock changes for the year ended March 31, 2024. The report showed that the Company's number of Class H ordinary shares listed on the Hong Kong Stock Exchange did not decrease during the month, amounting to 189,581,239 shares with a face value of RMB 1 per share. The share of Class A ordinary shares listed on the Shanghai Stock Exchange did not increase, amounting to 354,750,844 shares. In addition, under the A share incentive plan for 2022 and 2023, the company may issue new Class A ordinary shares totaling 2,498,330 shares. The Company confirms that all securities issues have been approved by the Board of Directors and are in compliance with relevant legal requirements.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more